FDA Approves Ziftomenib for Relapsed or Refractory Acute Myeloid Leukaemia with a NPM1 Mutation By Ogkologos - November 20, 2025 354 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the KO-MEN-001 study Source RELATED ARTICLESMORE FROM AUTHOR Belzutifan Plus Lenvatinib Improves Outcomes Over Cabozantinib in Patients with Advanced RCC Following Progression to PD1 or PD-L1 Inhibitors Combining 177Lu-PSMA-617 with ADT Plus ARPI Prolongs rPFS in Patients with PSMA-positive Metastatic Androgen Pathway Modulator-Naive/Sensitive Prostate Cancer EMA Recommends Extension of Therapeutic Indications for Cetuximab MOST POPULAR Navigating Your Care During Long-Term Cancer Survivorship June 25, 2020 EMA Recommends Extension of Therapeutic Indications for Nivolumab and Ipilimumab April 28, 2021 Pump Up the Volume: “Priming Agents” May Improve Cancer Liquid Biopsies February 22, 2024 Cancer Research UK spin-out gets US approval to trial unique T... June 18, 2021 Load more HOT NEWS Adjuvant Imatinib Prolongs RFS and OS in Patients with Resected GIST... The Appraisal – Scientific disruption: what is it, and do we... Study Provides Closer Look at Postmenopausal Bleeding and Endometrial Cancer How I Found a Meaningful Career After Cancer
